FDA’s draft guidance distinguishing between recalls and product enhancements was not well received by members of industry, who claim that the proposal requiring companies to submit “corrections and removals” reports for product enhancements would inappropriately insert recalls processes into pre-market review. AdvaMed and several individual device firms are calling for FDA to withdraw the guidance and issue a new one.
The draft guidance, issued in February, is an attempt by FDA to reassure companies that they can make an enhancement to a marketed device without worrying that the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?